UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2021
Commission File Number 001-15170
GlaxoSmithKline plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
GSK publishes provisional dividend dates
GSK announces the following dividend dates for 2022:
Results | Announcement date | Ex-dividend date | Record date | Last date for DRIP elections | Payable |
Q1 2022 | Wednesday 27 April 2022 | Thursday 19 May 2022 | Friday 20 May 2022 | Thursday 16 June 2022 | Thursday 7 July 2022 |
Q2 2022 | Wednesday 27 July 2022 | Thursday 18 August 2022 | Friday 19 August 2022 | Thursday 15 September 2022 | Thursday 6 October 2022 |
Q3 2022 | Wednesday 2 November 2022 | Thursday 17 November 2022 | Friday 18 November 2022 | Monday 19 December 2022 | Thursday 12 January 2023 |
Q4 2022 (Final) | Wednesday 1 February 2023 | Thursday 23 February 2023 | Friday 24 February 2023 | Tuesday 21 March 2023 | Thursday 13 April 2023 |
These dates are indicative and may be subject to change.
V A Whyte
Company Secretary
24 November 2021
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc | |
(Registrant) | |
Date: November 24, 2021 | |
By:/s/ VICTORIA WHYTE -------------------------- | |
Victoria Whyte | |
Authorised Signatory for and on | |
behalf of GlaxoSmithKline plc |